CDK2-IN-30, identified by its CAS number 2640038-22-6, is a chemical compound that serves as an inhibitor of cyclin-dependent kinase 2 (CDK2), an important enzyme involved in cell cycle regulation. This compound is characterized by its ability to selectively inhibit CDK2 activity, which can have significant implications in cancer research and therapy, as CDK2 is often overactive in various malignancies. The structure of CDK2-IN-30 typically includes specific functional groups that enhance its binding affinity to the CDK2 active site, thereby preventing the phosphorylation of target proteins necessary for cell cycle progression. Its efficacy and specificity make it a valuable tool in the study of cell cycle dynamics and the development of targeted cancer therapies. Additionally, the compound's pharmacokinetic properties, such as solubility and stability, are crucial for its potential therapeutic applications. As research continues, CDK2-IN-30 may contribute to the advancement of treatments aimed at controlling cell proliferation in cancerous tissues.

CDK2-IN-30

2640038-22-6: CDK2-IN-30, identified by its CAS number 2640038-22-6, is a chemical compound that serves as an inhibitor of cyclin-dependent kinase 2 (CDK2), an important enzyme involved in cell cycle regulation. This compound is characterized by its ability to selectively inhibit CDK2 activity, which can have significant implications in cancer research and therapy, as CDK2 is often overactive in various malignancies. The structure of CDK2-IN-30 typically includes specific functional groups that enhance its binding affinity to the CDK2 active site, thereby preventing the phosphorylation of target proteins necessary for cell cycle progression. Its efficacy and specificity make it a valuable tool in the study of cell cycle dynamics and the development of targeted cancer therapies. Additionally, the compound's pharmacokinetic properties, such as solubility and stability, are crucial for its potential therapeutic applications. As research continues, CDK2-IN-30 may contribute to the advancement of treatments aimed at controlling cell proliferation in cancerous tissues.

<p>CDK2-IN-30 (Formula (I)) is a CDK2 inhibitor with an IC50 of ≤20 nM, utilized primarily in tumor research.</p>

CAS 2640038-22-6

CDK2-IN-30

CDK2-IN-30

Ref: TM-T200706